الصفحة الرئيسية>>Signaling Pathways>> Microbiology & Virology>> Parasite>>Fexinidazole (HOE 239)

Fexinidazole (HOE 239) (Synonyms: HOE239)

رقم الكتالوجGC32094

Fexinidazole (HOE 239) (HOE 239) هو دواء فعال عن طريق الفم ومضاد للتريبانوزومات من nitroimidazole.

Products are for research use only. Not for human use. We do not sell to patients.

Fexinidazole (HOE 239) التركيب الكيميائي

Cas No.: 59729-37-2

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
35٫00
متوفر
5mg
32٫00
متوفر
10mg
32٫00
متوفر
50mg
44٫00
متوفر
100mg
61٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Fexinidazole is a 5-nitroimidazole drug currently in clinical development for the treatment of human sleeping sickness (human African trypanosomiasis [HAT]), caused by infection with species of the protozoan parasite Trypanosoma brucei. Target: Antiparasiticin vivo: Fexinidazole shows dose-related efficacy in the T. b. rhodesiense (STIB900) acute mouse model at intraperitoneal (i.p.) doses of 20 to 50 mg/kg/day and oral (per os [p.o.]) doses of 25 to 100 mg/kg/day given on four consecutive days, with 100 mg/kg/day p.o. being 100% curative. Fexinidazole is shown to be effective in the GVR35 mouse model, which mimics the advanced and fatal stage of the disease, when parasites have disseminated into the brain. [1]

[1]. Kaiser M, et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011 Dec;55(12):5602-8.

مراجعات

Review for Fexinidazole (HOE 239)

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fexinidazole (HOE 239)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.